Caplin Point Laboratories Limited (NSE:CAPLIPOINT)
2,096.50
+63.40 (3.12%)
Jun 8, 2026, 3:30 PM IST
Caplin Point Laboratories Stock Forecast
Stock Price Forecast
According to 2 analysts polled by S&P Global, Caplin Point Laboratories stock has a consensus rating of "Strong Buy" and an average price target of ₹2,505. The average 1-year stock price forecast is 19.48% higher than the current stock price, while the lowest is ₹2,320 (+10.66%) and the highest is ₹2,690 (+28.31%).
Price Target: ₹2,505 (+19.48%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Caplin Point Laboratories stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Jan '26 | Feb '26 | Mar '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 1 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 1 | 2 |
Financial Forecast
Revenue This Year
24.88B
from 21.87B
Increased by 13.75%
Revenue Next Year
28.05B
from 24.88B
Increased by 12.75%
EPS This Year
93.80
from 84.11
Increased by 11.52%
EPS Next Year
106.95
from 93.80
Increased by 14.02%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is INR.
Revenue Forecast
| Revenue | 2027 | 2028 |
|---|---|---|
| High | 25.0B | |
| Avg | 24.9B | |
| Low | 24.8B |
Revenue Growth
| Revenue Growth | 2027 | 2028 |
|---|---|---|
| High | 14.3% | |
| Avg | 13.8% | |
| Low | 13.2% |
EPS Forecast
| EPS | 2027 | 2028 |
|---|---|---|
| High | - | |
| Avg | 93.80 | |
| Low | - |
EPS Growth
| EPS Growth | 2027 | 2028 |
|---|---|---|
| High | - | |
| Avg | 11.5% | |
| Low | - |